Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,850 total articles
Universal Health Services (UHS) has traded down from its 2025 highs and now sits at single-digit multiples with an EV/EBITDA under 6 and free cash flow near $900M. With behavioral health tailwinds and the Talkspace acquisition nearing close, the risk/reward looks favorable for a tactical long over the next 180 trading days.
A 20-year, $6.6 billion contracted lease for CleanSpark's Georgia campus materially derisks the company's move from bitcoin mining to AI data-center infrastructure. The deal gives predictable revenue visibility, but negative free cash flow, elevated leverage and a history of capital raises mean dilution risk is real. This trade buys the current wea…
Origin Bancorp (OBK) is trading near its 52‑week high on a market cap of roughly $1.75B. With a conservative balance sheet (debt/equity ~0.01), free cash flow of ~$164M and a diversified community‑banking franchise, the next 45 trading days offer a mid‑term opportunity to buy into Texas exposure and earnings momentum. Entry $55.00, stop $51.00, tar…
Valero is a high-quality refiner sitting on robust margins and cash generation, but near-term execution on throughput and repair timelines will decide whether the stock reclaims its recent highs. This trade idea outlines a mid-term long setup that buys a manageable pullback ahead of/after the Q2 report, with a disciplined stop and concrete target.
Helios Technologies combines mid-single-digit organic growth potential with decent free cash flow and a conservative balance sheet. At $75.06 the stock offers a GARP (growth at a reasonable price) entry for investors willing to ride a cyclical recovery in construction, agriculture and marine end markets, with an upside path back toward the prior 52…
Halozyme's hyaluronidase platform and growing royalty streams have pushed the company into sustained free-cash-flow generation and attractive forward earnings. With 2026 guidance raised—total revenue of $1.71-$1.81B and adjusted EBITDA of $1.125-$1.205B—Halozyme looks priced for continued re-rating. This trade idea lays out an actionable long with …
Ovintiv offers a practical way to play stable free-cash generation, a conservative balance sheet, and upside from natural gas and Montney scale. Valuation looks inexpensive on EV/EBITDA and price/book metrics while the company returns capital through a dividend and continued asset monetizations. We lay out an actionable mid-term trade with explicit…
Berkshire Hathaway trades with a notable gap between market value and the sum of its large cash balance plus marketable securities and operating businesses. With a $1.12T market cap, a roughly $397B cash pile and a ~$350B public equities sleeve, a conservative sum-of-the-parts implies upside if management accelerates buybacks or redeploys cash into…
Microsoft’s platform-first strategy (Nebius-style PaaS) continues to underpin durable revenue and cash flow even as Copilot and agentic product setbacks create headline volatility. The company’s cash generation, healthy balance sheet, and cloud positioning give investors a margin of safety. This trade idea targets a disciplined entry at $392 with a…
Alphabet is growing Google Cloud at an eye-popping clip (82% y/y) and is plowing enormous capital into AI infrastructure ($45B last quarter; plans for $811B more). The business is healthy, but the pace and scale of AI spending threatens near-term cash generation and valuation support. We lay out a tactical short trade with entry, stop and target fo…
Honeywell (HON) offers a way to play steadily improving aerospace aftermarket economics: a large installed base, double-digit ROE, solid free cash flow and a 4%+ yield combine to create an attractive risk/reward for a long trade. Technical momentum and manageable short interest add tactical support while valuation is reasonable versus cash generati…
Credo (CRDO) has seen a brisk sell-off from recent highs but its fiscal momentum (fiscal 2026 revenue > $1.3B, net income ~$472M), pristine balance sheet and AI-driven demand for connectivity argue the drop is overdone. This trade plan targets a mid-term swing (45 trading days) entry at $190.00 with a $240.00 target and a $168.00 stop.
Take-Two shares trade at $247.62 where a modest $65M misread of GTA 6's early monetization equals roughly $0.34 per share. That small-per-share gap understates how preorder confirmation, live-service economics, and an improving free cash flow profile can re-rate the stock. This trade targets a move to $265 within 45 trading days while maintaining a…
Belite Bio (BLTE) is a clinical-stage biotech with a differentiated oral candidate, tinlarebant, that completed a rolling NDA submission for Stargardt disease type 1 and has Phase 3 data showing a meaningful clinical effect. The company has near-term regulatory catalysts, a healthy cash position, and clear commercialization preparation. This trade …
LPKFF is an OTC-listed specialist where the trade is about future commercial adoption rather than today's numbers. Technicals show the stock under pressure but not deeply beaten; short interest and intraday short activity have been volatile. This trade plan uses a disciplined entry, clear stop and a mid-term horizon to capture a rebound if adoption…
Adobe sits at the intersection of exploding generative content supply and businesses that need governance, tooling, and production-grade workflows. With double-digit revenue growth, $10.28B in free cash flow and a sub-14x P/E, Adobe offers a trade that pairs near-term momentum with multi-quarter optionality as enterprises professionalize AI content…
Rio Tinto (RIO) combines a generous ~4.4% yield, conservative valuation and improving technical momentum. With commodity-specific supply shocks (aluminum, constrained copper feedstocks) and a strategic pivot into higher-growth metals, the stock offers asymmetric upside over the next 46-180 trading days while carrying manageable downside if macro ri…
Netflix has traded off hard in the last year, but margins, cash generation and new revenue levers (ads, live sports, gaming) set the stage for a meaningful recovery. This trade lays out an actionable long-term long with clear entry, stop and target, and explains why the risk/reward favors buyers right now.
PureCycle Technologies is showing progress on the commercialization path: regulatory confirmations for food-contact PCR, a large capital raise to clean up expensive debt, and ongoing product wins. The market still prices in near-term failure — PCT trades at >100x sales and carries heavy short positioning. This trade idea is a tactical, mid-term lon…
SoundHound AI (SOUN) is trading near its 52-week low after a dramatic run-up into late 2025. The company operates in the voice and conversational AI layer - a market analysts peg near $47 billion by 2034 - and has shown strong revenue acceleration while still burning cash. This trade idea outlines a structured long with entry, stop, target, and a m…
Micron has been a runaway winner in 2026 but the tape has flipped into panic-mode. The company still prints massive returns on equity, strong free cash flow, and negligible leverage — fundamentals that support buying on a disciplined pullback. This trade idea lays out an entry, stop, and target for a long trade intended to capture a reversion towar…
Estee Lauder (EL) is aggressively repositioning for future growth — investing behind brands and channels while walking away from a merger to stay independent. The stock trades around $84.73 with a market cap near $31B, negative EPS, and stretched valuation metrics that assume a return to margin expansion. This trade idea outlines a tactical long ex…
Krystal Biotech is a commercial-stage gene-therapy specialist that is generating positive earnings, strong free cash flow, and multiple late-stage clinical readouts over the next 12 months. The stock is trading above its recent 52-week high, but the company's profitable base (EPS $7.63; FCF $237M) and large addressable market in rare dermatologic a…
Nordic American Tankers (NAT) has delivered on the thesis that drove my bullish stance last year: stronger tanker market conditions, fleet optimization and steady cash returns. At $6.41 the stock offers a compelling combination of yield and momentum. I lay out an actionable mid-term trade with entry, stop and target, plus catalysts and balanced ris…
I am upgrading American Airlines (AAL) to Buy. The stock is trading at a compelling implied enterprise valuation, recent corporate sustainability deals and event-driven demand should support revenue recovery, and technicals are neutral-to-constructive. This is a long-term trade (180 trading days) with a clear stop and target that balances upside op…
